Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...
New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing ...
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
AnaptysBio (NASDAQ:ANAB) stock maintained its Neutral rating and $19.00 price target from H.C. Wainwright. Currently trading ...
Following the agreement, Vanda is preparing BLA and MAA applications for the US and EU, with a focus on commercialization. Imsidolimab, a fully humanized IgG4 antibody, is expected to provide ...
Customs duty exemption in Budget for cancer drugs, rare diseases including SMA: Our Bureau, New Delhi Saturday, February 1, 2025, 15:20 Hrs [IST] The 36 life saving drugs and medi ...
Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic, ...
Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat.com reports. Four ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback